[en] INTRODUCTION: Our goals were to assess the prevalence of biological and tissue remission in routine practice in Crohn's disease, and to evaluate the correlation between biological or tissue remission and clinical or demographic characteristics as well as their impact on disease outcome. METHODS: We performed a retrospective monocenter study. Biological remission was defined by a CRP < 5 mg/I. Tissue remission was defined by the absence of ulcer at endoscopy and/or absence of signs of acute inflammation at MRI. Association with demographic, clinical and laboratory markers was studied by logistic regression models and rates of relapses, hospitalizations and surgeries were compared using the logrank test. RESULTS: Among the 263 patients included, 147 were in clinical remission; 102/147 (69%) were in biological remission. Fifty-six patients also had morphological evaluation: 37 (66%) were in tissue remission. Biological remission was associated with older age, higher hemoglobin and lower BMI. Tissue remission was associated with older age, lower platelets count, absence of previous surgery, and the use of immunosuppressant. Time-to-relapse was significantly longer in patients with biological remission and in patients with tissue remission as compared to patients without biological or tissue remission. CONCLUSIONS: Among the patients in clinical remission seen as outpatients, two thirds were either in biological and/or tissue remission. Biological and/or tissue remission was associated with a better outcome than clinical remission alone.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Poncin, Maxime ; Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive
REENAERS, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive
VAN KEMSEKE, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive
Belaiche, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Seidel, Laurence ; Université de Liège - ULiège > Département des sciences de la santé publique > Informatique médicale et biostatistique
MEUNIER, Paul ; Centre Hospitalier Universitaire de Liège - CHU > Service médical de radiodiagnostic
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Language :
English
Title :
Depth of remission in Crohn's disease patients seen in a referral centre : associated factors and impact on disease outcome.
Cellier C., Sahmoud T., Froguel E., Adenis A., Belaiche J., Bretagne J.F., Florent C., Bouvry M., Mary J.Y, Modigliani R. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gut, 1994, 35: 231-5.
Baert F., Moortgat L., Van Assche G., Caenepeel P., Vergauwe P., De Vos M., Stokkers P., Hommes D., Rutgeerts P., Vermeire S., D'Haens G., Belgian Inflammatory Bowel Disease Research Group, North -Holland Gut Club. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology, 2010, 138: 463-8.
Frøslie K.F., Jahnsen J., Moum B.A., Vatn M.H. and IBSEN group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology, 2007, 133: 412-22.
Louis E., Mary J.Y., Vernier-Massouille G., Grimaud J.C., Bouhnik Y., Laharie D., Dupas J.L., Pillant H., Picon L., Veyrac M., Flamant M., Savoye G., Jian R., Devos M., Porcher R., Paintaud G., Piver E., Colombel J.F., Lemann M. and GETAID. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology, 2012, 142: 63-70.
Rutgeerts P., Van Assche G., Sandborn W.J., Wolf D.C., Geboes K., Colombel J.F., Reinisch W.; EXTEND in vesti gators, Kumar A., Lazar A., Came z A., Lomax K., Pollack P.F, D'Haens G. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology, 2012, 142: 1102-1111.
Sandborn W.J., Panaccione R., Thakkar R., Lomax K.G., Chen N., Mulani P., Chao J., Yang M. Mucosal healing in adalimumab- treated patients is affected by duration of crohn's disease: results from EXTEND (Abstract). Gastroenterology, 2010, 138 (suppl 1): S-164.
Hovde Ø., Moum B.A. Epidemiology and clinical course of Crohn's disease: Results from observational studies. World J. Gastroenterol., 2012, 18: 1723-31.
Loly C., Belaiche J., Louis E. Predictors of severe Crohn's disease. Scand. J. Gastroenterol., 2008, 43: 948-54.
Treton X., Bouhnik Y., Mary J.Y., Colombel J.F., Duclos B., Soule J., Lerebours E., Cosnes J., Lemann M. and GETAID. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin. Gastroenterol. Hepatol., 2009, 7: 80-5.
Hass D.J., Brensinger C.M., Lewis J.D., Lichtenstein G.R. The impact of increased body mass index on the clinical course of Crohn's disease. Clin. Gastroenterol. Hepatol., 2006, 4: 482-8.
Peyrin-Biroulet L., Gonzalez F., Dubuquoy L., Rousseaux C., Dubuquoy C., Decourcelle C., Saudemont Z., Tachon M., Béclin E., Odou M.F., Neut C., Colombel J.F., Desreumaux P. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut, 2012, 61: 78-85.
D'Haens G., Geboes K., Rutgeerts P. Endoscopic and histologic healing of Crohn's ileo- colitis with azathioprine. Gastrointest. Endosc., 1999, 50: 667-71.
Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., Lichtiger S., D'Haens G., Diamond R.H., Broussard D.L., Tang K.L., Van der Woude J. and Rutgeerts P. For the SONIC Stud y group. Infliximab, Azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med., 2010, 362: 1383-1395.
Boirivant M., Leoni M., Tariciotti D., Fais S., Squarcia O., Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J. Clin. Gastroenterol., 1988, 10: 401-5.
Andre C., Descos I., Vignal J., Gillon J. C-reactive protein as a predictor of relapse in asymptomatic patients with Crohn's disease. Scott. Med. J., 1983, 28: 26-9.
Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., Hoffman I., Van Steen K., Vermeire S., Rutgeerts P. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm. Bowel Dis., 2009, 15: 1295-301.